The Current and Future Landscape of Healthcare IPO Markets

Back Bay Life Science Report

With the DNB//Back Bay Partnership for Healthcare

In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public this year, including Schott Pharma, Germany’s largest IPO earlier this year.

In the first podcast episode with the DNB//Back Bay Partnership for Healthcare, Jonathan Gertler, Back Bay CEO and Managing Partner is joined by Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equity Capital Markets at DNB, and Vasilios Kofitsas, Partner and Managing Director of Investment Banking at Back Bay Life Science Advisors, to discuss the current landscape of IPO and capital markets, optimal preparation strategies for companies hoping to go public and why it ultimately matters who you spend your time with.

Topics in this episode include:

• Dynamics leading to the current IPO market and capital markets landscape
• The state of private and partnering markets and the renewed power of partnerships
• Crucial roles of private investments, VC and other “mezzanine investors” for public emergence licensing
• The importance of optimal prep and aftermarket support, and why spending good time in the preparation phase with both research and individual investor meetings is a key success factor, regardless of where companies are planning to list
• The ever-important lesson of starting early